Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy

Asian Journal of Andrology

Volumn 12, Issue 2, 2010, Pages 171-179

  Zhou, Li Xin ^a   Li, Tao ^a   Huang, Yi Ran ^a   Sha, Jian Jun ^a   Sun, Peng ^a   Li, Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Biochemical recurrence; Histone modification; Immunohistochemistry; Prostate cancer; Radical prostatectomy; Tissue microarray

Indexed keywords

HISTONE; HISTONE H3; HISTONE H4; LYSINE; PROSTATE SPECIFIC ANTIGEN;

ACETYLATION; ARTICLE; CANCER LOCALIZATION; CANCER RECURRENCE; CANCER RISK; CONTROLLED STUDY; DEMETHYLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; PHASE PARTITIONING; PREDICTION; PREOPERATIVE PERIOD; PROSTATE CANCER; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN MODIFICATION; RISK ASSESSMENT; TISSUE MICROARRAY;

AGED; HISTONES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; METHYLATION; MIDDLE AGED; PROSTATECTOMY; RECURRENCE;

EID: 77749283802     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2009.81     Document Type: Article

References (39)

1. Han M, Partin AW, Piantadosi S, Epstein JI, Walsh PC. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol 2001; 166: 416-9.
2. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004; 7: 211-6.
3. Brenner H. Long-term survival rates of cancer patients achieved by the end of the 20th century: a period analysis. Lancet 2002; 360: 1131-5.
4. Molitierno J, Evans A, Mohler JL, Wallen E, Moore D, et al. Characterization of biochemical recurrence after radical prostatectomy. Urol Int 2006; 77: 130-4.
5. Lapointe J, Li C, Higgins JP, van de Rijn M, Bair E, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. PNAS 2004; 101: 811-6.
6. Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 2007; 97: 1-5.
7. Lund AH, Lohuizen MV. Epigenetics and cancer. Genes Dev 2004; 18: 2315-35.
8. Ducass M, Brown MA. Epigenetic aberrations and cancer. Mol Cancer 2006; 5: 60.
9. Kuendgen A, Lübbert M. Current status of epigenetic treatment in myelodysplastic syndromes. Ann Hematol 2008; 87: 601-11.
10. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-53.
11. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415-28.
12. Rundlett SE, Carmen AA, Suka N, Turner BM, Grunstein M. Transcriptional repression by UME6 involves deacetylation of lysine 5 of histone H4 by RPD3. Nature 1998; 392: 831-5.
13. Park YS, Jin MY, Kim YJ, Yook JH, Kim BS, et al. The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma. Ann Surg Oncol 2008; 15:1968-76.
14. Vogelauer M, Wu J, Suka N, Grunstein M. Global histone acetylation and deacetylation in yeast. Nature 2000; 408: 495-8.
15. Millar CB, Grunstein M. Genome-wide patterns of histone modifications in yeast. Nat Rev Mol Cell Biol 2006; 7: 657-66.
16. Li LC, Carroll PR, Dahiya R. Epigenetic changes in prostate cancer: implication for diagnosis and treatment. J Natl Cancer Inst 2005; 97: 103-15.
17. Kurdistani SK, Tavazoie S, Grunstein M. Mapping global histone acetylation patterns to gene expression. Cell 2004; 117: 721-33.
18. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 2006; 6: 107-16.
19. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006; 7: 21-33.
20. Seligson DB, Horvath S, Shi T, Yu H, Tze S, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005; 435: 1262-6.
21. Gleason DF. Histologic Grading and Clinical Staging of Prostatic Carcinoma; In: Tannenbaum M, editor. Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger, 1977, p171-98.
22. National Comprehensive Cancer Network. National Comprehensive Cancer Network (NCCN) Prostate Cancer Guideline, V1. 2009.
23. Kononen J, Bubendorf L, Kallioniemi A, Bärlund M, Schraml P, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 4: 844-7.
24. Frutos-Vivar F, Ferguson ND, Esteban A, Epstein SK, Arabi Y, et al. Risk factors for extubation failure in patients following a successful spontaneous breathing trial. Chest 2006; 130: 1664-71.
25. Kharbanda AB, Taylor GA, Fishman SJ, Bachur RG. A clinical decision rule to identify children at low risk for Appendicitis. Pediatrics 2005; 116: 709-16.
26. R Development Core Team. R: a language and environment for statistical computing. Vienna, R Foundation for Statistical Computing, 2008, Available via http://www.R-project.org
27. Freedland SJ, Humphreys EB, Mangold LA, Eisenberger M, Dorey FJ, et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 2005; 294: 433-9.
28. Gibbons RJ. Histone modifying and chromatin remodeling enzymes in cancer and dysplastic syndromes. Hum Mol Genet 2005; 14: R85-92.
29. Tokumaru Y, Harden SV, Sun DI, Yamashita K, Epstein JI, et al. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004; 10: 5518-22.
30. Jerónimo C, Henrique R, Hoque MO, Ribeiro FR, Oliveira J, et al. Quantitative RARβ2 hypermethylation: a promising prostate cancer marker. Clinical Cancer Res 2004; 10: 4010-4.
31. Dobosy JR, Roberts JL, Fu VX, Jarrard DF. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 2007; 177: 822-31.
32. Sakr WA, Tefilli MV, Grignon DJ, Banerjee M, Dey J, et al. A heterogeneous entity? Correlation with pathologic parameters and disease-free survival. Urology 2000; 56: 730-4.
33. Rice KR, Furusato B, Chen Y, McLeod DG, Sesterhenn IA, et al. Clinicopathological behavior of single focus prostate adenocarcinoma. J Urol 2009 October 16 [Epub ahead of print].
34. Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, et al. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 2003; 170:1860-3.
35. Klein EA, Bianco FJ, Serio AM, Eastham JA, Kattan M W, et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J Urol 2008; 179: 2212-7.
36. Turner BM. Defining an epigenetic code. Nat Cell Biol 2007; 9: 2-6.
37. He J, Kallin EM, Tsukada Y, Zhang Y. The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15Ink4b. Nat Struct Mol Biol 2008; 15: 1169-75.
38. Esteller M. Molecular origins of cancer: epigenetics in cancer. N Engl J Med 2008; 358: 1148-59.
39. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281: 1591-7.